Literature DB >> 22172534

Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics.

Tsutomu Kikuchi1, Kunihiro Iwamoto, Kazumi Sasada, Branko Aleksic, Keizo Yoshida, Norio Ozaki.   

Abstract

This study aimed to estimate the prevalence of sexual dysfunction, evaluated by the Nagoya Sexual Function Questionnaire (NSFQ), and hyperprolactinemia in patients with schizophrenia and examine a relationship between sexual dysfunction and serum prolactin levels. This cross-sectional, comparative study was performed using a sample comprising 195 Japanese schizophrenic in- and outpatients treated with antipsychotics (117 males and 78 females). Data were collected from October 2009 to January 2010 using single, cross-sectional ratings of sexual function assessed by the NSFQ and concurrent measurement of serum prolactin levels. The prevalence of sexual dysfunction in patients with schizophrenia was high (males 66.7%; females 79.5%). Hyperprolactinemia (>25ng/ml) was highly prevalent among schizophrenia patients, affecting 53.8% of females and 51.3% of males. Among female patients, 16.7% had prolactin levels>100ng/ml. There was no relationship between sexual dysfunction and serum prolactin levels. The present study demonstrated a higher prevalence of sexual dysfunction and hyperprolactinemia in Japanese schizophrenia patients. Clinicians should keep these problems in mind and discuss potential solutions with patients to improve patients' quality of life and adherence to therapy. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172534     DOI: 10.1016/j.pnpbp.2011.11.016

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  5 in total

Review 1.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

2.  Women's sexual dysfunction associated with psychiatric disorders and their treatment.

Authors:  Rosemary Basson; Thea Gilks
Journal:  Womens Health (Lond)       Date:  2018 Jan-Dec

3.  Assessment of sexual dysfunction and associated factors among patients with schizophrenia in Ethiopia, 2017.

Authors:  Tolesa Fanta; Kibrom Haile; Dessie Abebaw; Dawit Assefa; Getahun Hibdye
Journal:  BMC Psychiatry       Date:  2018-05-29       Impact factor: 3.630

4.  What is the "weight" of body mass index on sexual functioning in women? A mediation model.

Authors:  Maria Di Nardo; Chiara Conti; Giulia Di Francesco; Giulia Nicolardi; Maria Teresa Guagnano; Piero Porcelli
Journal:  Eat Weight Disord       Date:  2020-09-12       Impact factor: 4.652

5.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.